Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Commercial Deals M & A

Deal Watch: DelMar Takes On Unmet Need In Brain Cancer With Accurexa

Executive Summary

Getting ready to take VAL-083 into Phase III in recurrent glioblastoma, DelMar also is partnering with Accurexa to develop an implantable wafer therapeutic combining the drug with other brain cancer chemotherapies. GW Pharmaceuticals sees a surge in its share price as speculation mounts about a possible takeout.

You may also be interested in...



GW Pharma High On Epilepsy Results, Plans 2017 NDA

The biotech announces another set of positive anti-seizure results for its marijuana-derived product.

PIPELINE WATCH - Four Launches, Two Approvals And Six Orphan Drug Designations

The table records clinical and regulatory developments using data from BioMedTracker. It lists all drugs for which an event was recorded from April 15 to April 21, 2016, divided by event type.

Structure Emerges In Obesity Race With Oral GLP-1 Agonist

Early-stage data with Structure’s oral GSBR-1290 shows weight loss of 4.9% at four weeks, which appears to top Lilly’s oral GLP-1 data in a Phase Ia trial.

Table

View full table

Topics

Related Companies

Related Deals

Tags:
Commercial Deals M & A
Latest Headlines

Finance Watch: Adlai Nortye Raises $97.5m In IPO, Brings US Total To 18

Amicus Piggybacks Off Galafold Commercial Infrastructure For Pombiliti + Opfolda Launch

Structure Emerges In Obesity Race With Oral GLP-1 Agonist

ViiV In It For The Long Haul In HIV Market Battle With Gilead

See All
UsernamePublicRestriction

Register

SC097268

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By